Edesa Biotech to Present New Data on Paridiprubart in Acute Kidney Injury at European Nephrology Conference

Edesa Biotech Reports Fiscal 2nd Quarter 2026 Results

Edesa Biotech Invited for Oral Showcase at Respiratory Innovation Summit

Edesa Biotech Advances Vitiligo Program for Planned Mid-2026 Enrollment

Edesa Biotech Reports Additional Positive Results from Phase 3 Paridiprubart Study

Market Today: AI Fears Rattle Stocks; CPI Cools, Rivian Pops

Edesa Biotech Reports Fiscal 1st Quarter 2026 Results

Edesa Biotech Reports Fiscal Year 2025 Results

Edesa Biotech Announces Upcoming Conference Schedule

Edesa Biotech Reports Positive Results in Phase 3 Respiratory Study

Edesa Biotech Posts Narrower Loss in Q3

Edesa Biotech Reports Fiscal 3rd Quarter 2025 Results

Edesa Biotech Reports Fiscal 2nd Quarter 2025 Results

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Edesa Biotech Announces Chief Financial Officer Transition

Edesa Biotech Reports Fiscal 1st Quarter 2025 Results

Edesa Biotech Announces $15.0 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Edesa Biotech Reports Fiscal Year 2024 Results

Edesa Biotech's Founder Makes Strategic Investment in the Company

Edesa Biotech Announces Upcoming Conference Schedule

Pardeep Nijhawan Provides Update to Beneficial Ownership of Securities of Edesa Biotech, Inc.

Edesa Biotech Reports Fiscal 3rd Quarter 2024 Results

BARDA Selects Edesa Biotech's Drug for U.S. Funded Platform Trial in General ARDS

Edesa Biotech Reports Fiscal 2nd Quarter 2024 Results

Edesa Biotech to Participate in Bloom Burton Healthcare Investor Conference

Edesa Biotech to Participate in Upcoming Investor Conferences

Edesa Biotech to Participate in HC Wainwright Autoimmune & Inflammatory Conference

Edesa Biotech to Participate in Barclays Global Healthcare Conference

Edesa Biotech to Participate in Upcoming Dermatology Meetings

Edesa Biotech Reports Fiscal 1st Quarter 2024 Results

Edesa Biotech to Participate in Dermatology Summit and JP Morgan Week

Edesa Biotech Reports Fiscal Year 2023 Results

Edesa Biotech Reports Final Phase 2b Results for Dermatitis Study

Edesa Biotech to Present at Dermatology Drug Development Summit

Regulators Approve Updated Phase 3 Trial Design for Edesa Biotech's ARDS Drug

Edesa Biotech Secures $10 Million Credit Facility with Company Founder

Edesa Biotech to Receive Up To C$23 Million in Funding from Federal Government

Edesa Biotech Announces One-for-Seven Reverse Share Split

Edesa Biotech Publishes Phase 2 Substudy Results of ARDS Drug Candidate

Edesa Biotech Reports Fiscal Third Quarter 2023 Results

Edesa Biotech to Participate in Upcoming Canaccord Genuity Growth Conference

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

What Is Going on With Edesa Biotech (EDSA) Stock Today?

Edesa Biotech to Present at Upcoming H.C. Wainwright Investor Conference

Edesa Biotech to Present at ARDS Drug Development Summit

Edesa Biotech to Present at H.C. Wainwright Global Investment Conference

Edesa Biotech: Leader In Developing Treatments For COVID-19 And ACD

Canada Approves Edesa Biotech's COVID-19 Trial For EB05 Antibody As Rescue Therapy

Edesa Biotech Shares Gain As Its COVID-19 Antibody Shows Favorable Mortality Reductions

Why Edesa Biotech Shares Are Trading Higher Today